About Us

We are a biopharmaceutical company focused on discovering and developing small molecule kinase inhibitors to address existing and emerging unmet needs in oncology. With a precision oncology approach, our aim is to improve survival and enhance overall well-being for cancer patients. 

Our discovery process combines clinically validated biological targets and industry-leading chemistry with the goal of designing best-in-class and first-in-class therapies. By focusing on these targets, we aim to develop drugs with a high probability of clinical success.

Learn more about our approach

Our Team

We have assembled a team with significant expertise in drug discovery and development with particular strength in the discovery of small molecule kinase inhibitors. Our team includes:

  • World-renowned chemists who have been the primary or co-inventor of over 20 product candidates that have been advanced to clinical trials, including four FDA-approved cancer therapies: Koselugo (selumetinib), Mektovi (binimetinib), Tukysa (tucatinib), and Retevmo (selpercatinib).
  • Precision oncology and kinase inhibitor experts who have led or been involved with the discovery and development of over 60 small molecule kinase inhibitor programs, including Imbruvica (ibrutinib), Vitrakvi (larotrectinib), Zydelig (idelalisib), ipatasertib (AKT inhibitor), and PF-07284890/ARRY-461 (CNS-penetrant BRAF inhibitor).
  • Leaders with a track record of success who have built or led research and development operations at companies including AbbVie, Array BioPharma, Genentech, Biogen, Pharmacyclics, Five Prime Therapeutics-Amgen, Gilead Sciences, and Blueprint Medicines.
Sam_Kintz photo

Sam Kintz, MBA

Co-founder, Chief Executive Officer, and Member of the Board of Directors

Joe Lyssikatos photo

Joe Lyssikatos, PhD

Co-founder, Chief Scientific Officer, and Member of the Board of Directors

Anish Patel photo

Anish Patel, PharmD

Co-founder and Chief Operating Officer

Helen Collins photo

Helen Collins, MD

Chief Medical Officer

Ben Hohl photo

Ben Hohl

Chief Financial Officer

Board of Directors

Scientific Advisors

Investors

logo 5am ventures

logo boxer capital

logo cormorant asset management

logo janus henderson investors

logo logos capital

logo roche venture fund

logo sheatree capital

logo surveyor